Research
Hormonal
GLP-1 receptor agonists (Liraglutide, Semaglutide, Tirzepatide) are effective for chronic weight management in obese patients, but improper use without clinical indication can lead to serious side effects.
GLP-1 drugs like Semaglutide and Tirzepatide are effective for weight loss in obese patients with comorbidities. However, they are prescription medications with serious side effects. Do not use them without medical indication or supervision. Follow your doctor's dosage and monitoring plan.
GoodQualifiesHIGH confidence
Semaglutide (Ozempic) has recently come to the fore as a drug used by celebrities and endorsed on social media for weight-loss purposes... Careless use of Semaglutide can lead to serious side effects, such as pancreatitis, kidney failure, serious allergic reactions, and possible thyroid tumors.
Why this rating
Based on multiple RCTs and FDA approvals cited.
Source
Obesity and Cardiovascular Risk: Systematic Intervention Is the Key for Prevention
Francesco Perone et al. · Healthcare · 2023
DOI 10.3390/healthcare11060902
narrative_reviewCited 39×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Cardiac rehabilitation programs significantly improve exercise capacity, cardiovascular risk factors, and psychological well-being in obese patients, regardless of baseline cardiovascular disease status.Good
- Weight cycling (yo-yo dieting) is associated with increased cardiovascular risk and morbidity, whereas sustained weight loss or maintenance reduces risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →